Coronavirus 1300 GMT 07 Mar

A/K/A the [China, South Korea, Italy, Iran] Virus:

95% of total cases in those four countries 88% of active cases in those four countries 86% of new cases in last 24 hours in those four countries

US report: five days of 7-8 serious cases is encouraging. This stability means when a death takes someone off this list they are being replaced with a new serious patient at about the same rate. Personally sad of course but public health perspective encouraging. If serious number starts to grow it is serious.

The South Korea [serious]/[active] ratio, applied to the US, suggests about 1500 active cases in US. South Korea has best DNA testing data.

US testing is the gap between 335 ‘total cases’ reported here and the untested, asymptomatic 1165 or so because US testing is just coming on line. So expect an artificial ‘surge’ in US cases over next week as DNA evidence replaces clinical symptoms.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies

Dr. Steven Quay investigates COVID-19's origins, analyzing evidence that suggests SARS-CoV-2 may have resulted from a lab incident rather than natural transmission. Through statistical methods, Dr. Quay estimates a 98% probability of a lab origin, challenging popular theories about animal-to-human transmission and highlighting possible lab safety issues in Wuhan. In this video, he also emphasizes the importance of global safety regulations to prevent future pandemics. Watch to uncover key insights on COVID-19's origins and why lab safety matters for global health.

This video describes the clinical data from the Atossa Therapeutics press release of October 31, 2024 entitled, Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer